DCM
MREO

DAFNA Capital Management’s Mereo BioPharma MREO Stock Holding History

DAFNA Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-778,813
Closed -$1.8M – 78
2023
Q4 		$1.8M Sell
778,813
-183,700
-19% -$351K 0.43% 45
2023
Q3 		$1.24M Sell
962,513
-46,500
-5% -$61.7K 0.39% 49
2023
Q2 		$1.33M Sell
1,009,013
-87,500
-8% -$101K 0.36% 47
2023
Q1 		$775K Hold
1,096,513
– – 0.23% 52
2022
Q4 		$822K Hold
1,096,513
– – 0.23% 55
2022
Q3 		$944K Hold
1,096,513
– – 0.25% 59
2022
Q2 		$1.23M Sell
1,096,513
-120,100
-10% -$93.1K 0.33% 58
2022
Q1 		$1.36M Buy
1,216,613
+90,000
+8% +$116K 0.36% 63
2021
Q4 		$1.8M Hold
1,126,613
– – 0.45% 47
2021
Q3 		$2.73M Hold
1,126,613
– – 0.72% 38
2021
Q2 		$3.57M Sell
1,126,613
-123,035
-10% -$413K 0.75% 35
2021
Q1 		$4.21M Buy
1,249,648
+581,500
+87% +$2.06M 1% 29
2020
Q4 		$2.39M Buy
668,148
+468,723
+235% +$1.17M 0.71% 36
2020
Q3 		$522K Buy
199,425
+122,625
+160% +$358K 0.17% 73
2020
Q2 		$235K Buy
+76,800
New +$135K 0.07% 83

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

DAFNA Capital Management's MREO Position: Q1 2024 in Review

DAFNA Capital Management sold out of Mereo BioPharma (MREO) in Q1 2024, closing a stake of 778,813 shares — an estimated $1.8M sold.

DAFNA Capital Management first reported a position in MREO in Q2 2020 and held it in 15 quarters. The position peaked at $4.21M in Q1 2021. 80 funds tracked by Wall St. Rank hold MREO as of Q1 2024.

  • DAFNA Capital Management reported no remaining Mereo BioPharma position as of Q1 2024 after selling out during the quarter.
  • DAFNA Capital Management sold 778,813 Mereo BioPharma shares in Q1 2024, an estimated $1.8M.
  • DAFNA Capital Management first reported a position in Mereo BioPharma in Q2 2020 and held it in 15 quarters.
  • DAFNA Capital Management's Mereo BioPharma position peaked at $4.21M in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2024.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.